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Aims To evaluate the associations of emergent genome-wide-association study-derived coronary heart disease (CHD)-
associated single nucleotide polymorphisms (SNPs) with established and emerging risk factors, and the association
of genome-wide-association study-derived lipid-associated SNPs with other risk factors and CHD events.
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Methods
and results
Using two case–control studies, three cross-sectional, and seven prospective studies with up to 25 000 individuals
and 5794 CHD events we evaluated associations of 34 genome-wide-association study-identified SNPs with CHD
risk and 16 CHD-associated risk factors or biomarkers. The Ch9p21 SNPs rs1333049 (OR 1.17; 95% confidence
limits 1.11–1.24) and rs10757274 (OR 1.17; 1.09–1.26), MIA3 rs17465637 (OR 1.10; 1.04–1.15), Ch2q36
rs2943634 (OR 1.08; 1.03–1.14), APC rs383830 (OR 1.10; 1.02, 1.18), MTHFD1L rs6922269 (OR 1.10; 1.03, 1.16),
CXCL12 rs501120 (OR 1.12; 1.04, 1.20), and SMAD3 rs17228212 (OR 1.11; 1.05, 1.17) were all associated with
CHD risk, but not with the CHD biomarkers and risk factors measured. Among the 20 blood lipid-related SNPs,
LPL rs17411031 was associated with a lower risk of CHD (OR 0.91; 0.84–0.97), an increase in Apolipoprotein AI
and HDL-cholesterol, and reduced triglycerides. SORT1 rs599839 was associated with CHD risk (OR 1.20; 1.15–
1.26) as well as total- and LDL-cholesterol, and apolipoprotein B. ANGPTL3 rs12042319 was associated with CHD
risk (OR 1.11; 1.03, 1.19), total- and LDL-cholesterol, triglycerides, and interleukin-6.
Conclusion Several SNPs predicting CHD events appear to involve pathways not currently indexed by the established or emer-
ging risk factors; others involved changes in blood lipids including triglycerides or HDL-cholesterol as well as LDL-
cholesterol. The overlapping association of SNPs with multiple risk factors and biomarkers supports the existence of
shared points of regulation for these phenotypes.
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Introduction
Alterations in a number of intermediate phenotypes or bio-
markers (such as blood lipid fractions, inflammation, or coagu-
lation proteins) precede and are associated with a higher risk
of coronary heart disease (CHD) events. With the exception
of LDL-cholesterol (LDL-C) for which there is additional evi-
dence from interventional trials, inability to exclude bias
arising from confounding and reverse causation, precludes firm
conclusions being drawn about their causal relevance using
observational data alone.1 Genome wide association studies
(GWAS) are less affected by confounding or by reverse associ-
ation bias because genotype is determined by randomized allo-
cation and fixed from conception.2 – 4 However single
nucleotide polymorphisms (SNPs) associated with common dis-
eases including CHD have typically been in non-coding DNA,
distant from annotated genes, or in chromosomal regions
where associated SNPs span several different equally plausible
candidates.5 – 7 This can make it difficult to infer the mechanisms
linking genome variation to clinical endpoints simply from
genomic location.
Integration of information on genotype, intermediate pheno-
types, and disease endpoints could provide insight into the mech-
anism by which disease-associated SNPs alter cardiovascular risk
and help better define the causal relevance of cardiovascular bio-
markers. However, the emphasis of most GWAS, thus far, has
rightly been on the robust detection of genetic signals with a
single phenotype (or narrow range of phenotypes, e.g. blood
lipids) or one disease endpoint at a time.8
The large number of CHD cases needed to conduct adequately
powered genetic association studies is most efficiently assembled
using a case–control design,7 but preclinical risk factors and
disease biomarkers have been best characterized in population-
based cohort studies, which individually accrue fewer cases.9
Because genotype is determined at conception, and invariant, it
becomes possible to undertake large-scale genetic meta-analyses
that include information from both types of study to maximize
available information on both biomarkers and disease
endpoints.10,11
Using a collaboration of 12 studies, involving 25 000 individ-
uals, we typed the first SNPs to be identified from GWAS (from
2007 to 2008) that were associated either with myocardial infarc-
tion (MI) or with an intermediate phenotype previously associated
with MI risk including LDL-C, HDL-cholesterol (HDL-C), triglycer-
ides (TG), body mass index (BMI), or type-2 diabetes mellitus
(T2DM).5,12– 19 We studied the associations of these SNPs with
a wider range of intermediate phenotypes, to elucidate shared
points of regulation, and with CHD risk to assess if the biomarkers
altered are likely to mediate or mark changes in the causal pathway
to CHD.
First, we hypothesized that comparative analysis of SNP associ-
ations with cardiovascular disease (CVD) risk factors/biomarkers
and CVD endpoints would help delineate the mechanisms linking
genetic variation to CVD events. Identifying which biomarker-
associated SNPs also alter disease risk should help clarify which
biomarkers lie in the causal pathway. Conversely, understanding
which risk factors/biomarkers are altered by disease-associated
SNPs should help elucidate the mechanisms underlying the
disease association where these are uncertain. Second, we
hypothesized that since non-genetic biomarkers are frequently
correlated, SNPs identified for an index association with one
CVD risk factor/biomarker would frequently be associated with
a diverse array of other risk factors/biomarkers. Studying of the
effect of a SNP on many phenotypes (a phenome scan) would
define common points of regulation for diverse risk factors and
help disentangle the causal from non-causal interconnections
between correlated lipid and inflammation and coagulation
markers. By helping to evaluate which SNP associations are exclu-
sive to a single risk factor and which are more extensive, these
analyses should also inform on the specificity of individual SNPs
for Mendelian randomization analyses of biomarkers and risk
factors.
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Methods
Data sets
Prospective studies
Seven UK prospective studies contributed to the collaboration: North-
wick Park Heart Study II (NPHS II),20 British Regional Heart Study
(BRHS),21 English Longitudinal Study of Ageing (ELSA),22 Edinburgh
Artery Study (EAS),23 the 1958 Birth Cohort (1958BC),24 the MRC
1946 Birth Cohort (MRC 1946),25 and the Whitehall II Study
(WHII).26 Six studies (NPHS II, BRHS, ELSA, EAS, 1958BC, and
MRC 1946) were population based, while Whitehall II was workplace
based. The details of the sampling frame, inclusion criteria, duration of
follow-up, and other details are listed in Supplementary material
online, Methods 1 and Table S1.
Cross-sectional studies
Two cross-sectional studies contributed prevalent cases of CHD: the
Southampton Atherosclerosis Study (SAS)27 and the Stockholm
Heart Epidemiology Program (SHEEP).28 The SHEEP study included
contemporaneous controls, while the representative, population-
based cohort study NPHS II, in which participant recruitment over-
lapped geographically with that for SAS, acted as a control data set
for SAS. Details of design, matching criteria, recruitment, main demo-
graphic details, definition of outcomes, and other measures are
described in Supplementary material online, Methods 1 and Table
S1. Two cross-sectional studies included individuals without CHD
but with a diagnosis of T2DM (based on individuals with a fasting
glucose level ≥7.0 mmol/L or non-fasting glucose ≥11.1 mmol/L,
or self-reported use of anti-diabetic medication): the UCL Diabetes
and Cardiovascular Disease Study (UDACS)29 and the Ealing Dia-
betes Study (EDS)30 (Supplementary material online, Methods 1
and Table S1). One cross-sectional study, the MRC-BHF British Gen-
etics of Hypertension (BRIGHT) study31 included individuals without
CHD but with high blood pressure (BP) (Table 1).
Measures
Demographic and other variables
Age, gender, BMI, and systolic and diastolic BP were available from all
studies (Table 1).
Blood biomarkers
The availability of blood lipids and apolipoproteins (ApoBs), indices
of glycaemic control, as well as inflammation, coagulation, and meta-
bolic markers are listed in Table 1. All measurements were made
using validated assays and protocols whose details have been
reported previously (Supplementary material online, Methods 1)
and all markers were assayed in subjects free from CHD at the
time of sampling. For prospective studies, these samples were
obtained either from the baseline survey or from a subsequent res-
urvey closest to the assessment at which the study DNA repository
was established.
Clinical outcomes
We defined coronary heart disease as a composite endpoint of non-
fatal MI, CHD death, or coronary revascularization procedure using
prevalent and incident events. We used a similar approach to that
adopted by the CARDIoGRAM consortium for defining CHD end-
points.32 We defined incident events in cohort studies as occurring
after establishment of the DNA repository and prevalent events as
those non-fatal events preceding the establishment of a DNA reposi-
tory. Subjects from the SAS study were sampled on the condition of
having coronary stenosis ≥50% of the diameter in at least one
major coronary artery (defined by coronary angiography rather than
clinical CHD event).
Genotyping
We typed 21 SNPs associated with LDL-C, HDL-C, TG, or BMI and a
total of 16 SNPs previously shown to exhibit an association with CHD
or T2DM from GWAS reported in 2007 and 2008. All SNPs that were
significant with a P-value ,1025 identified from GWAS were included
for the analysis unless they were in linkage disequilibrium (LD). Where
SNPs were in LD, the best proxy was chosen based on feasibility for
genotyping to provide the maximum data available for the analysis.
Two SNPs from the chromosome 9p21 region were selected as
they had both been identified from GWAS. However, since
rs10757274 had not been typed in HapMap at the time this analysis
was initiated, and the degree of LD with other SNPs on ch9p21 was
not known, both SNPs were included. Details are provided in
Table 2. New genotyping was conducted using validated, high through-
put genotyping platforms at the Genome Centre, Queen Mary Univer-
sity of London, using Kaspar technology or the ABI TaqMan platform;
Medical Solutions, Nottingham, using the ABI SNPplex platform; or the
Centre for Cardiovascular Genetics UCL, using the ABI TaqMan plat-
form (Table 1). The Whitehall II study provided genotypes from the
ITMAT/Broad Institute CARE consortium (IBC) Human CVD Beadchip
(Illumina) while 1958BC and BRIGHT provided genotypes from the
Affymetrix 500K whole genome array.
Analysis
We regarded a SNP association in CBGC with the same endpoint as
that reported in the discovery GWAS as a replication analysis. Single
nucleotide polymorphism associations in CBGC with outcomes dis-
tinct from the original discovery GWAS e.g. evaluation of associations
of CHD-associated SNPs with risk factors and biomarkers were
regarded as a discovery analysis.
Single nucleotide polymorphism associations with
coronary heart disease
Seven studies including NPHS II, BRHS, ELSA, EAS, WHII, SAS, and
SHEEP contributed to the meta-analysis of the association of genotype
with CHD (Table 1). The meta-analysis utilized summary data from
individual studies using a protocol agreed jointly by a central analysis
subgroup in conjunction with principal investigators and statisticians
from the participating studies. All analyses were restricted to individ-
uals of Caucasian ethnicity and limited to subjects with complete
data for gender, age, and genotype.
For the purposes of quality control and to allow evaluation of any
genetic heterogeneity between studies, each study provided details
of genotyping platform, call-rate, minor allele frequency (MAF), the
exact P-value for a test of departure from Hardy–Weinberg equili-
brium (HWE) in subjects without clinical evidence of CHD, and con-
cordance rates for duplicate genotyping. We pre-specified a threshold
call rate of 90%, but included SNPs with call rates .80% provided the
MAF was concordant with other studies, genotype error rates were
,1%, and the P-value for deviation for HWE exceeded 0.001. The pre-
specified analysis plan is included as Supplementary material online,
Methods 2. Genotypes were coded using a standardized designation
for homozygous and heterozygous individuals. Individuals homozygous
for the common allele served as the reference group for all the
comparisons.
Each contributing study estimated an unadjusted and adjusted OR
(and standard error) for CHD, for each additional rare allele carried
(i.e. a trend analysis using an additive model on the logarithmic
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Table 1 Studies contributing to the Cardiovascular Biomarker Genetics Collaboration (see Appendix 1 for further details)
NPHS-II BRHS ELSA EAS WH-II 1958BC MRC 1946 SAS SHEEP UDACS EDS BRIGHT-cases Total
Study designa Prospective
cohort
Prospective cohort Prospective
cohort
Prospective
cohort
Prospective
cohort
Prospective
birth
cohort
Prospective
birth cohort
Cases with
angiographic
coronary
disease
Cases of
CHD
and
controls
Cross-sectional Cross-sectional Cases from case–
control study of
hypertension
Sampling frame General
practices
General practices Respondents
of HSE
General
practices
Workplace Birth register Birth register CHD patients Swedish
citizens
Diabetic
patients
Diabetic
patients
General practices
N with DNA 2775 3947 5274 940 5500 1480 2700 1164 2698 575 331 1759
Genotyping
method
TaqMan SNPlex SNPlex TaqMan IBC 50k CVD
chip
Affy 500k SNPlex KASPAR KASPAR TaqMan TaqMan Affy 500k
% men 100 100 48 50 77 50 50 76 69 59 60 40
Years follow-up 17 26 10 20 20 51 63 NA NA — — 10
Mean (SD) age of
participants
56.1 (3.4) 48.9 (5.50) from 1978
to 1980; 68.8
(5.49) from 1998
to 2000
64 64.3 (5.63) 60.9 (6.0) 45 53 at year of
collection
now 63
63.4 59.6 (7.15) 66.7 (11.0) 63.5 (13.8) 54.6 (10.1)
Baseline year 1989–94 1978–80 1998, 1999,
2001
1987 1985–88 1958 1946 2000–01 1992–94 2001 2001–02 1996
Cases of CHD 273a 724b 140c 117b 241c NA NA 1164c 1213c NA NA NA 3872
Cases of T2D 229b 595b 249c NA 336c NA NA NA NA 600 331 NA 2340
BMI 2746 3863 5257 893 4789 1436 2455 NA 1052 554 301 1732 25 078
Systolic BP 2747 3860 5342 892 4803 1431 2439 NA 1055 556 320 1759 25 204
Diastolic BP 2747 3860 5341 890 4803 1431 2439 NA 1050 556 319 1759 25 195
Pulse P 2747 3860 5341 890 4803 1431 2439 NA NA 556 319 1759 24 145
Total cholesterol 2742 3845 5406 892 4799 1416 2321 NA 1496 556 311 1502 25 286
LDL cholesterol 1735 3732 5264 887 4741 1338 2145 NA 1482 541 269 1502 23 636
HDL cholesterol 1836 3735 5404 887 4799 1413 2155 NA 1487 556 289 1503 24 064
Triglycerides 2742 2745 5406 892 4799 1415 2319 NA 1496 556 289 1502 24 161
ApoAI 2344 NA NA NA 4637 NA NA NA 1495 NA NA NA 8476
ApoB 2344 NA NA NA 4637 NA NA NA 1495 NA NA NA 8476
Homocysteine 1361 3776 NA NA NA NA NA NA 1116 NA NA NA 6253
HbA1c NA 3792 5405 NA 4759 1414 2333 NA NA 553 303 NA 18 559
Glucose NA 3843 3224 891 4791 NA NA NA 1363 556 315 NA 14 983
Insulin NA 2717 NA NA 4259 NA NA NA 1124 NA NA NA 8100
Fibrinogen 2733 3834 5436 874 4357 1416 NA NA 1403 NA NA NA 20 053
IL-6 NA 2258 NA 628 4274 NA NA NA 801 546 NA NA 8507
C-reactive
protein
2279 3833 5404 605 4663 1418 NA NA 1115 545 82 NA 19 944
aIncident cases only.
bBoth prevalent and incident cases.
cPrevalent cases only; NA: not available.
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scale) as well as for subjects heterozygous or homozygous for the rare
allele compared with those homozygous for the common
allele. Variables used in the adjustment were age (in 5 year bands,
e.g. 50–55, etc.), gender (male vs. female), and smoking (ever vs.
never). A summary odds ratio (95% confidence interval) for the risk
of CHD for each SNP was calculated by fixed effects meta-analysis
using the Mantel–Hanzel method as well as by random effects
meta-analysis using the DerSimonian and Laird method. Where avail-
able, we included estimates from the Wellcome Trust Case Control
Consortium 1 (WTCCC1) study of CHD5 in the meta-analysis. A
false discovery rate (FDR)-adjusted P-value was calculated based on
the number of hypotheses tested.33 Defining FDR as the proportion
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Categories of single nucleotide polymorphisms typed by the Cardiovascular Biomarkers Genetics
Collaboration
SNP Gene Chr Allele 1a Allele 2 Initial discovery studyb
CHD SNPs
rs599839 SORT1 1 A G Samani (2007)
rs17465637 MIA3 1 C A Samani (2007)
rs17672135 FMN2 1 T C WTCCC (2007)
rs2943634 intergenic 2 C A Samani (2007)
rs383830 APC 5 T A WTCCC (2007)
rs6922269 MTHFD1L 6 G A Samani (2007)
rs1333049 CDKN2B (d) 9 G C WTCCC (2007)
rs10757274 CDKN2B (d) 9 A G McPherson (2007)
rs501120 CXCL12 (d) 10 C T Samani (2007)
rs1994016 ADAMTS7 15 C T WTCCC (2007)
rs17228212 SMAD3 15 T C Samani (2007)
rs8055236 CDH13 (d) 16 T G WTCCC (2007)
rs7250581 VSTM2B 19 A G WTCCC (2007)
rs688034 SEZ6L 22 C T WTCCC (2007)
T2D SNPs
rs10811661 CDKN2B (d) 9 C T Saxena (2007)
rs9939609 FTO 16 T A Frayling (2007)
HDL SNPs
rs17411031 LPL 8 C G Wallace (2008)
rs3890182 ABCA1 9 G A Kathiresan (2008)
rs261332 LIPC 15 G A Wallace (2008)
rs9989419 CETP 16 G A Willer (2008)
rs16979595 CLPTM1 19 G A Wallace (2008)
LDL SNPs
rs599839 SORT1 1 A G Willer (2008)
rs562338 APOB 2 A G Willer (2008)
rs688 LDLR 19 C T Wallace (2008)
rs4420638 APOC1/APOE 19 A G Willer (2008)
Triglyceride SNPs
rs12042319 ANGPTL3 1 G A Wallace (2008)
rs3917820 SELP 1 G A Wallace (2008)
rs12140698 FAM5B (d) 1 C T Wallace (2008)
rs780094 GCKR 2 C T Willer (2008)
rs1471233 intergenic 4 C T Wallace (2008)
rs2074755 BAZ1B 7 T C Wallace (2008)
rs17482753 LPL 8 G T Wallace (2008)
rs4740635 intergenic 9 G C Wallace (2008)
rs7861175 LPAR1 (d) 9 T C Wallace (2008)
rs6589566 APOA5 11 A G Wallace (2008)
rs7229921 CIDEA (d) 18 A G Wallace (2008)
(d) refers to the nearest downstream gene.
aAllele 1 is the reference allele for all comparisons.
bInitial discovery studies are Samani (2007);12 WTCCC (2007);5 McPherson (2007);13 Saxena (2007);19 Frayling (2007);18 Wallace (2008);15 Kathiresan (2008);16 Willer (2008).14
Comparative analysis of loci for lipids, diabetes, and CHD 397
of falsely rejected hypotheses, i.e. for which the null was actually true,
this new P-value, known as the q-value,34 is the minimum FDR when
rejecting a null hypothesis from a list of tested null hypothesis, con-
ditioned on at least one positive finding having occurred.
Single nucleotide polymorphism associations with
continuous risk factors and biomarkers
Eleven studies including NPHS II, BRHS, ELSA, EAS, WHII, 1958BC,
MRC 1946, SHEEP, UDACS, EDS, and BRIGHT contributed to the
analysis of SNP associations with continuous risk factors and bio-
markers. The distributions of TG, homocysteine, C-reactive
protein, and interleukin-6 (IL-6) were skewed in all studies and
these variables were log transformed and analysed on the log-scale.
For each SNP, we performed a linear regression analysis within study
for each continuous biomarker assuming an additive effect of each
variant allele. The per-allele regression coefficient, which is equal
to the weighted per-allele mean difference, was then divided by
the pooled standard deviation of the trait of interest, derived
using information from each of the three genotypes categories; to
calculate the standardized mean difference (and its corresponding
standard error). Further details are provided in Supplementary
material online, Methods 2 with information on the STATA
do-files. Separate analyses were conducted unadjusted and adjusted
for all of age (in 5 year bands, e.g. 50–55, etc.), gender (male vs.
female), and smoking (ever vs. never). We used random and fixed
effect meta-analysis to pool the within-study estimates for each
trait to generate a summary per-allele standardized mean difference
(and 95% confidence interval) to allow comparison of SNP effects
across different traits on a common scale. For all traits, the mean
of the standardized mean differences is 0 and the standard deviation
1. In the absence of consensus regarding statistical significance level
for reporting SNP-associations with multiple traits or disease end-
points (pleiotropy), we reported all results as point estimates and
95% confidence limits (although P-values are available in the Sup-
plemental material online). An FDR-adjusted P-value (q-value) was
also calculated based on the number of hypotheses tested.33 Sup-
plementary material online, Methods 3 provides a detailed discussion
of sample size and study power in the context of the range of con-
firmatory and exploratory analyses that we conducted.
Results
Study populations and measures
The age range of the study populations was 44–67 years. Two
studies were of men only (NPHS II and BRHS) while in the remain-
der, the proportion of men was between 48 and 72% of partici-
pants. Among the prospective studies with incident events, the
length of follow-up was between 10 and 26 years. The two
case–control studies (SHEEP and SAS) (2377 cases), and five of
the seven prospective studies (1495 cases) contributed to the
analysis of CHD outcomes (Table 1). The control subjects from
SHEEP, participants with BP but no CHD from BRIGHT, and the
participants from all cross-sectional and cohort studies contributed
to the analyses of SNP effects on risk factors and biomarkers
(Table 1). Information was available on BMI from 25 078
participants, and systolic and diastolic BP from 25 204 and
25 195 participants, respectively. The blood biomarkers measured
spanned lipids and lipoproteins, indices of glycaemic control,
inflammation, and coagulation including: total cholesterol (TC; n
¼ 25 286), HDL-C (n ¼ 24 064), LDL-C (n ¼ 23 636), fasting, or
non-fasting TGs (n ¼ 24,161), ApoA1 (n ¼ 8476), ApoB (n ¼
8476), C-reactive protein (n ¼ 19 944), IL-6 (n ¼ 8507), fibrinogen
(n ¼ 20 053), fasting glucose (n ¼ 14 983), fasting insulin (n ¼
8100), glycated haemoglobin (HbA1c; n ¼ 18,559), and homocys-
teine (n ¼ 6253).
Single nucleotide polymorphisms
previously identified for an association
with coronary heart disease
There was a strong concordance of MAFs across studies; see Sup-
plementary material online, Tables S1–S3 for call rates, MAF and
tests for departure from HWE. Of the 14 SNPs selected
through an association with CHD, the following nine SNPs were
associated with CHD events in a fixed effects meta-analysis: two
at chromosome 9p21 (rs1333049, OR 1.17; 1.11–1.24 and
rs10757274, OR 1.17; 1.09–1.26), and one each near SORT1
rs599839 (OR 1.20; 1.15–1.26), MIA3 rs17465637 (OR 1.10;
1.04–1.15), Ch2q36 rs2943634 (OR 1.08; 1.03–1.14), APC
rs383830 (OR 1.10; 1.02–1.18), MTHFD1L rs6922269 (OR 1.10;
1.03–1.16), CXCL12 rs501120 (OR 1.12; 1.04–1.20), and SMAD3
rs17228212 (OR: 1.11; 1.05–1.17) (Figure 1 and Supplementary
material online, Table S4). Supplementary material online, Figure
S1 provides estimates from a random effects model. However,
aside from rs599839, none of these CHD SNPs was associated
with any of the wide range of risk factors and biomarkers analysed,
despite available information from 20 000 or more participants for
TC, LDL-C, HDL-C, TG, BMI, BP, fibrinogen, and C-reactive
protein, over 15 000 for HbA1c, 10 000 for fasting glucose, and
just under 10 000 for IL-6 and fasting insulin (Figures 2 and 3).
Single nucleotide polymorphisms
previously identified for an association
with blood lipids
Seventeen of 20 SNPs selected because of an initial association
with a blood lipid component were associated with the same
lipid fraction in the CBGC studies (Figure 3 and Supplementary
material online, Table S4). The overlap with SNPs identified by
the recent Global Lipids Genetics Consortium (GLGC)
meta-analysis35 is shown in Supplementary material online,
Table S7. However, in all cases the effect of this category of
SNPs was found to extend beyond the initial reported lipid
fraction. For example, ANGPTL3 rs12042319 was associated with
BMI, TC, LDL-C, and IL-6 in addition to the reported association
with TG (Supplementary material online, Figure S2). Another
SNP, LIPC rs261332 whose initial reported association was with
HDL-C, also showed additional associations with ApoAI, TC,
fasting insulin, and TG (Supplementary material online, Figure S3).
A summary profile of associations for all the SNPs analysed with
all the biomarkers measured is shown in Figure 3. The range and
direction of associations was distinctive for each SNP. For
example, of the five SNPs associated with HDL-C (CLPTM1
rs16979595, LPL rs17411031, LIPC rs261332, ABCA1 rs3890182,
and CETP rs9989419), all had a different pattern of association
with other risk factors and biomarkers. For some SNPs, the
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associations extended across a wider range of CHD biomarkers
e.g. for GCKR rs780094, associations encompassed lipids and
ApoB (TC and TG) as well as the inflammation markers C-reactive
protein and fibrinogen (Supplementary material online, Figure S4).
Of the SNPs in this category, only three were associated with
CHD (Figure 1); LPL rs17411031 whose initial association was
with HDL-C (OR 0.91; 0.84–0.97) (Figure 4), SORT1 rs599839
whose initial association was with LDL-C (OR 1.20; 1.15–
1.26), and ANGPTL3 rs12042319 whose initial association was
with TG (OR 1.11; 1.03–1.19) (Supplementary material online,
Figure S2).
Single nucleotide polymorphisms
previously identified for an association
with type-2 diabetes or adiposity
Neither of the two SNPs typed whose initial association was with
T2DM (Ch9p21 rs10811661 and FTO rs9939609) or adiposity (FTO
Figure 1 Forest plot of associations of 34 single nucleotide polymorphisms identified by GWAS for association with coronary heart disease
risk, type-2 diabetes or adiposity or blood lipids with coronary heart disease events. Odds ratios (95% CI) are presented for the Cardiovascular
Biomarker Genetics Collaboration data with WTCCC1 data where available using a fixed effects model.
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rs9939609) was associated with CHD in the current analysis.
However, we observed associations of the FTO SNP with variables
incorporated in one or more definitions of the metabolic syn-
drome including systolic BP, TG and HDL-C (but not LDL-C),
and C-reactive protein, in addition to fasting insulin and glucose,
HbA1c, and BMI (Figures 3 and 5).
Discussion
Genome wide association studies have had resounding success in
identifying genetic variants contributing to individual differences
in the levels of established and emerging risk factors and CHD
events.5,6,11,19,35,36 Genome wide association studies thus far
have typically been designed to assess associations of many hun-
dreds of thousands of SNPs usually with a single risk factor or
disease endpoint at a time. However, many cardiovascular risk
factors and biomarkers are correlated, and scores of alleles are
thought to contribute to any common disease or traits,37 so it
has been hypothesized that overlapping genetic associations
with multiple phenotypes are likely to be frequent. For
example, SNPs in the SH2B3 gene has been associated with
celiac disease, rheumatoid arthritis, eosinophil count, high BP,
and MI.5,6,38 – 40
In the current analysis, we systematically tested the extent to
which SNPs identified through an initial association with a lipid
fraction, diabetes, or CHD risk are related to a wider range of
intermediate phenotypes. The aim was to identify common
points of regulation among correlated risk factors and biomarkers
and to evaluate which intermediate phenotypes are likely to lie in
or mark changes in the causal pathways involved in CHD.
Single nucleotide polymorphisms initially
identified for an association with coronary
heart disease events
The well-studied Ch9p21 SNPs (rs1333049 and rs10757274) were
significantly associated with the endpoint of CHD events, defined
as prevalent MI (in SHEEP), incident/prevalent CHD events (in the
prospective observational studies) or angiographic CAD (in SAS).
However, neither of these SNPs nor the lead SNPs in SMAD3,
MIA3, CXCL12, MTHFD1L, or Ch2q36 were associated with
T2DM or any of the CHD biomarkers studied including BMI, BP,
blood lipids, and ApoBs, the inflammation markers IL-6, fibrinogen,
Figure 2 Association of rs1333049 in the CDKN2B region on chromosome 9 with coronary heart disease-related risk factors and biomarkers.
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and C-reactive protein, or a number of markers of glycaemic status
including fasting glucose and insulin as well as HbA1c. Given that
the combined data set included over 20 000 observations for
BMI, BP, TC, HDL-C and LDL-C, TG, C-reactive protein, and fibri-
nogen and over 10 000 for fasting glucose and HbA1c and the fact
that these traits are continuous rather than dichotomous
measures, the effect estimates we obtained are likely to be
precise and based on adequately powered analysis. The FDR for
many of the identified trait associations have a q-value ,1025,
suggesting that the majority of these are likely to be true.
However, we could not exclude very minor effects on these or
other traits. Prior studies of these CHD-associated SNPs (including
the initial GWAS) have reported a lack of association with blood
lipids and BP or with clinically defined hypertension or hyperlipi-
daemia, but the breadth and detail of intermediate phenotypes
studied previously has not been as great as in the current
Figure 3 (A) Matrix of associations between the 34 single nucleotide polymorphisms analysed, continuous risk factors and biomarkers, and
coronary heart disease events. Each cell is colour coded according to the P-value for the relevant association. (B) Matrix of associations between
the 34 single nucleotide polymorphisms analysed, continuous risk factors and biomarkers, and coronary heart disease events. Each cell is colour
coded according to the beta-coefficient from the pooled regression analysis (i.e. effect size) for the relevant association.
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study.5,12,13,41,42 The association of these SNPs with clinical events
despite the absence of association with a wide range of established
and emerging cardiovascular risk factors suggests their effects are
mediated through a previously unsuspected disease mechanism.
Additional fine mapping analyses will be required to demarcate
the likely causal variants and functional studies to help identify
the disease mechanisms.
Lead SNPs in genomic regions including SEZ6L, VSTM2B, CDH13,
ADAMTS7, and FMN2 that were associated with CHD in initial
GWAS,5,12 were not associated with CHD events in the current
data set, broadly consistent with a recent analysis from the Coron-
ary Artery Disease Consortium which included 11 000 cases of
CHD or MI.41
Single nucleotide polymorphisms initially
identified for an association with lipids
With the exception of three SNPs identified previously to be
associated with TG (SELP rs3917820, Ch9p24 rs4740635,
CIDEA rs7229921), we replicated associations of 17 other SNPs
with LDL-C, HDL-C, or TG. Each of these 17 variants had
additional effects on other lipids or ApoBs, at least equal in
size to the index association, and some also had effects on
other phenotypes such as inflammation markers or glycaemic
indices.
Although many of these phenotypes are inter-correlated, the
profile of associations was distinctive for each SNP (Figure 3),
arguing that SNPs associated with several phenotypes have a
true biological basis. For example, of the five SNPs associated
in the same direction with HDL-C, only two were associated
with TG; however, the direction of the effect was different. A
similar situation was observed for SNPs originally associated
with TG. These marked differences in the patterns of SNP
associations contrast with the observed almost invariable associ-
ation between HDL-C and TG levels.43 Genetic studies in popu-
lations have been likened to natural randomized trials and we
have previously reported on concordant effects on blood lipids
and lipoproteins of CETP SNPs and treatment with a
CETP-inhibitor.44 Genome wide association studies have also
reported associations of SNPs in the HMGCR gene (which
encodes the target for statins) with LDL-C and CHD risk.16,17
Single nucleotide polymorphisms in the gene PPARG that
encodes the target for glitazone drugs have also been shown
to influence the risk of T2DM.19,45 This suggests that the SNPs
Figure 4 Association of rs17411031 in LPL with triglycerides, HDL-cholesterol, and Apolipoprotein AI.
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associated with blood lipids and other biomarkers could help to
profile the likely effects of pharmacological modification of the
same targets. The diverse effect profiles of SNPs associated
with HDL-C indicate that not all therapeutic approaches for
HDL-C elevation with the aim of coronary prevention are
likely to be equally effective and that the choice of target may
matter as much as the elevation of HDL-C per se.
The ANGPTL3 SNP rs12042319 was associated with increased
CHD risk but with lower LDL-C, TG, and IL-6 levels, all of
which have themselves been associated with increased risk of
CHD.46 –48 Although ANGPTL3 has been associated with TG and
LDL-C levels,35 it has not been previously associated with CHD
risk in GWAS analysis or in the recent pooled analysis.49 There-
fore, the CHD association we observed should be considered
hypothesis generating, and any relevant mechanism is deserving
of further investigation. The LPL SNP rs17411031 was associated
with a lower risk of CHD and with lower TG and higher HDL-C
values. Other SNPs in this gene have previously been shown to
affect TG, HDL-C, and CHD risk,14– 17,19,50 and a recent analysis
of a common variant in the APOA5 gene that is functionally
linked with LPL, is also associated with TG, HDL-C, and CHD
risk.51,52,47 These findings suggest further studies of the ApoAV/
LPL pathway should be performed to evaluate it as a possible
therapeutic target for coronary prevention.
Single nucleotide polymorphisms initially
identified for an association with body
mass index or diabetes
We studied two SNPs identified with an index association with
T2DM, one of which (FTO rs9939609) is thought to act through
a primary effect on adiposity and BMI. Neither of these SNPs
was associated with CHD in this study, however, the FTO SNP
was associated with higher BMI, systolic BP, fasting insulin and
glucose, HbA1c, TG, and C-reactive protein, as well as a lower
HDL-C. The International Diabetes Federation (http://www.idf.
org/metabolic_syndrome) defines metabolic syndrome as the pres-
ence of central obesity (indexed by waist circumference) together
with the presence of two of the following: raised BP, raised TGs,
raised fasting glucose, and reduced HDL-C. Our findings are also
in keeping with those reported previously from a meta-analysis
of 17 000 participants.53 Taken together, the findings suggest
that targeting FTO itself or FTO-mediated effects may be effective
Figure 5 Association of rs9936909 in FTO with components of the metabolic syndrome.
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in reducing the risk of metabolic syndrome and, perhaps, its down-
stream consequences on disease risk as recently suggested.54
Limitations
Our analysis was limited to SNPs identified by the first wave of
GWAS, and although the list of variants influencing CHD, blood
lipids, diabetes, and BMI has since increased substantially, the
first SNPs to be identified are likely to represent the largest
effect sizes. Our analysis represents one of the first attempts to
study the effect of SNPs from GWAS relevant to cardiovascular
disease on a wide range of cardiovascular phenotypes as well as
CHD. The study is well powered to achieve this, and for
example, a sample size of 7000 subjects would be required to
be able to discover SNPs that explain as little as 0.5% of the var-
iance with 80% power, and for the majority of traits we far
exceed this number. The approach we have taken could now be
extended to incorporate both a wider range of SNPs from sub-
sequent GWAS as well as a wider range of phenotypes, to build
a more comprehensive picture of the repertoire of SNPs affecting
each of the cardiovascular risk factors and biomarkers as well as
the repertoire of traits affected by any given SNP, and to integrate
this information with the risk of clinical disease endpoints.
The GLGC analysis was a recent hugely important and success-
ful effort to discover and replicate additional loci for four lipid
traits: total-, LDL-, and HDL-C, as well as TGs. For the SNPs
that were present in both our study and the GLGC, the directions
of effect were concordant as shown in Supplementary material
online, Tables S5–S7. However, the GLGC did not have the oppor-
tunity to study the wide range of inflammation, coagulation, and
glycaemic markers that we have been able to report on in the
present work. Although the GLGC analysis investigated the associ-
ation of lipid-associated loci with CHD risk in 24 607 CAD cases
compared with 5794 cases in the current analysis (see Supplemen-
tary material online, Table S7), many of the SNPs we studied were
already identified for their association with CHD risk. Neverthe-
less, our findings should be interpreted within the context of the
available power of the study and the potential for false positive
association. There may also have been heterogeneity of effect esti-
mates among the different sample collections evidenced by the
high I2 values for many of the pooled analyses, and the reasons
for this potential heterogeneity are worthy of further investigation,
though some could be attributed to the differences in study design.
Ongoing collaborative GWAS in CHD should help to clarify the
role of these loci and also unveil additional smaller effect loci
underlying susceptibility to CHD.
Conclusions
The unique properties of genotype, which are distinct from other
natural differences between individuals, provide new opportunities
for evaluating causal links between associated intermediate pheno-
types and between phenotypes and disease. Our findings demon-
strate that there are likely to be important unsuspected disease
mechanisms and therapeutic targets for CHD; and that there
may be points of regulation for diverse cardiovascular risk
factors and biomarkers. In future, enhancing the level of detail at
both genetic and phenotypic level, incorporating transcriptomics,
metabolomics, as well as structural imaging should provide a
more comprehensive understanding of the mechanisms linking
genome variation with disease. In turn, this should help the devel-
opment of additional effective therapies for cardiovascular disease
prevention.
Supplementary material
Supplementary material is available at European Heart Journal
online.
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